Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis

British Journal of Dermatology

Volumn 159, Issue 6, 2008, Pages 1322-1330

  Wollenberg, A ^a   Sidhu, M K ^b   Odeyemi, I ^b   Dorsch, B ^c   Koehne Volland, R ^c   Schaff, M ^d   Ehlken, B ^d   Berger, K ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^c Metronomia GmbH   (Germany)

^d Medical Economics Research Group (MERG)   (Germany)

Author keywords

Atopic dermatitis; Cost analyses; Health related quality of life; Outcomes; Prophylactic treatment

Indexed keywords

TACROLIMUS;

ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; ECONOMIC EVALUATION; FEMALE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; COST-BENEFIT ANALYSIS; DERMATITIS, ATOPIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH CARE COSTS; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; QUALITY OF LIFE; TACROLIMUS; YOUNG ADULT;

EID: 56549125052     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08807.x     Document Type: Article

References (37)

1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980 92 (Suppl. 44 7.
2. Merk H. Clinical symptoms of atopic dermatitis. In : Handbook of Atopic Eczema (Ruzicka T, Ring J, Przybilla B, eds). Berlin : Springer Verlag, 1991 27 30.
3. Carroll CL, Balkrishnan R, Feldman S et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005 22 : 192 9.
4. Larsen FS, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2002 22 : 1 25.
5. Schäfer T, Vieluf D, Behrendt H et al. Atopic eczema and other manifestations of atopy: results of a study in East and West Germany. Allergy 1996 51 : 532 9.
6. Weiland SK, von Mutius E, Hirsch T et al. Prevalence of respiratory and atopic disease disorders among children in East and West of Germany five years after unification. Eur Respir J 1999 14 : 862 70.
7. Williams HC. Epidemiology of atopic dermatitis: recent advances and future predictions. Curr Probl Dermatol 1999 28 : 9 17.
8. Statistisches Bundesamt. Spezialbericht Allergien. Stuttgart : Metzler Poeschel Verlag, 2000.
9. Kissling S, Wüthrich B. Verlauf der atopischen Dermatitis nach dem Kleinkindalter [Follow-up of atopic dermatitis after early childhood]. Hautarzt 1993 44 : 569 73.
10. Emerson RM, Charman CR, Williams HC. The Nottingham Eczema Severity Score: preliminary refinement of the Rajka and Langeland grading. Br J Dermatol 2000 142 : 288 97.
11. Darsow U, Lübbe J, Taieb A et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005 19 : 286 95.
12. Barbeau M, Lalonde H. Burden of atopic dermatitis in Canada. Int J Dermatol 2006 45 : 31 6.
13. Zuberbier T, Orlow SJ, Paller AS et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006 118 : 226 32.
14. Charman C, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000 142 : 931 6.
15. Morris A. Effects of long-term topical corticosteroids. Dermatol Pract 1998 6 (3 5 8.
16. Hague J, Berth-Jones J. Current management of atopic eczema in primary care. Prescriber 2005 16 : 50 7.
17. Alomar A, Berth-Jones J, Bos JD et al. European Working Group on Atopic Dermatitis. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004 151 (Suppl. 70 3 27.
18. Gieler U, Hohmann M, Niemeier V et al. Cost evaluation in atopic eczema. J Dermatolog Treat 1999 10 (Suppl. 1 15 21.
19. Augustin M, Zschocke I. Lebensqualität und Ökonomie bei allergischen Hauterkrankungen. Allergologie 2001 24 : 433 42.
20. Ehlken B, Möhrenschlager M, Kugland B et al. Krankheitskostenstudie bei Patienten mit atopischem Ekzem in Deutschland [Cost-of-illness study in patients with atopic eczema in Germany]. Hautarzt 2005 56 : 1141 51.
21. Wollenberg A, Reitamo S, Girolomoni G et al. Proactive treatment of atopic dermatitis in adults with 0·1% tacrolimus ointment. Allergy 2008 63 : 742 50.
22. Hanifin JM. EASI correlates with IGA and validates its use as a measure of atopic eczema. Presented at 61st Annual Meeting of the American Academy of Dermatology, 21-26 March 2003, San Francisco, CA, U.S.A. Abstr. P210 Liste. Arzneimittelverzeichnis für Deutschland [Tariff List for Drugs in Germany]. Aulendorf : Editio Cantor Verlag, 2005.
23. Kassenärtzliche Bundesvereinigung. Einheitlicher Bewertungsmaßstab (EBM 2000 plus) [German Tariff List for Medical Services]. Available at: http://www.ebm2000plus.de (last accessed 4 June 2008).
24. Institut für das Entgeltsystem im Krankenhaus (InEK). Fallpauschalenkatalog 2006. Available at: http://www.g-drg.de (last accessed 4 June 2008).
25. Bundesministerium für Gesundheit und Soziale Sicherung. Verordnung zur Bestimmung vorläufiger Landes-Basisfallwerte im Fallpauschalensystem für Krankenhäuser für das Jahr 2005. Available at: http://www.bmg.bund.de/nn_603204/SharedDocs/Gesetzestexte/Krankenhaeuser/ Fallpauschalenverordnung-2005,templateId=raw,property=publicationFile.pdf/ Fallpauschalenverordnung-2005.pdf (last accessed 4 June 2008).
26. Statistisches Bundesamt. Statistisches Jahrbuch 2005 für die Bundesrepublik Deutschland. Wiesbaden : Metzler-Poeschel, 2005.
27. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 21 : 271 92.
28. Berth-Jones J, Damstra RJ, Golsch S et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003 326 : 1367.
29. Abramovits W, Hung P, Tong KB. Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis. Am J Clin Dermatol 2006 7 : 213 22.
30. Ellis CN, Drake LA, Prendergast MM et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol 2003 48 : 553 63.
31. Coyle D, Barbeau M. Cost effectiveness of Elidel in the management of patients with atopic dermatitis in Canada. J Cutan Med Surg 2004 8 : 405 10.
32. Hjelmgren J, Svensson A, Jorgensen ET et al. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. Br J Dermatol 2007 156 : 913 21.
33. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006 61 : 969 87.
34. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007 214 : 289 95.
35. Orlow SF. Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues. Pediatr Drugs 2007 9 : 289 99.
36. Drummond MF, O'Brien B, Stoddart GL, Torrance GW (eds). Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford : Oxford University Press, 1997.
37. Garside R, Stein K, Castelnuovo E et al. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technol Assess 2005 9 : 1 230.